Autophagy as a Possible Mechanism of Resistance in pNET Treatment
#1111
Introduction: Pancreatic neuroendocrine tumor (pNET) patients often display primary or secondary resistance to Sunitinib, an anti-angiogenic multi-receptor tyrosine kinase inhibitor which has been approved for the treatment of late stage pNETs. In late cancer stage autophagy often has a tumor promoting role. Sunitinib might additionally activate autophagy through inhibition of mTOR or induction of hypoxia.
Aim(s): To assess whether autophagy acts as a mechanism of resistance in late stage pNETs and if autophagy inhibition increases therapy efficacy
Materials and methods:
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Wiedmer T, Marinoni I, Tschan M, Perren A,
Keywords: pNET, autophagy, Sunitinib, resistance,
To read the full abstract, please log into your ENETS Member account.